JPH04149114A - Whitening cosmetic - Google Patents
Whitening cosmeticInfo
- Publication number
- JPH04149114A JPH04149114A JP27193890A JP27193890A JPH04149114A JP H04149114 A JPH04149114 A JP H04149114A JP 27193890 A JP27193890 A JP 27193890A JP 27193890 A JP27193890 A JP 27193890A JP H04149114 A JPH04149114 A JP H04149114A
- Authority
- JP
- Japan
- Prior art keywords
- ascorbic acid
- whitening
- formulas
- acid derivative
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 28
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 239000000126 substance Substances 0.000 claims abstract 6
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims abstract 5
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 20
- 238000003860 storage Methods 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 238000011084 recovery Methods 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 239000000839 emulsion Substances 0.000 abstract description 4
- 239000006210 lotion Substances 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 239000004215 Carbon black (E152) Substances 0.000 abstract 2
- 229930195733 hydrocarbon Natural products 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 1
- 239000002304 perfume Substances 0.000 abstract 1
- 239000000049 pigment Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 12
- 102000003425 Tyrosinase Human genes 0.000 description 11
- 108060008724 Tyrosinase Proteins 0.000 description 11
- 150000000996 L-ascorbic acids Chemical class 0.000 description 10
- 229960005070 ascorbic acid Drugs 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 235000010323 ascorbic acid Nutrition 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- -1 fatty acid ester Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000003977 halocarboxylic acids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- BYTCDABWEGFPLT-UHFFFAOYSA-L potassium;sodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[K+] BYTCDABWEGFPLT-UHFFFAOYSA-L 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野〕
本発明は新規な美白化粧料に関する。さらに詳しくは、
ビタミンC−E誘導体を含有することを特徴とする、美
白効果及び保存安定性に優れた美白化粧ネ4に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a novel whitening cosmetic. For more details,
This invention relates to a skin whitening makeup product 4 that is characterized by containing a vitamin C-E derivative and has excellent whitening effects and storage stability.
[従来の技術〕
一般にシミ、ソバカス3 日焼けなどに見られる皮膚の
色素沈着は、皮膚内に存在するヂロシンがチロシナーゼ
の作用ムこより酸化されてメラニンとなり、このメラニ
ンが過剰に生成することに基因するとされている。[Prior art] Spots and freckles in general 3 It is believed that the pigmentation of the skin, which is seen due to sunburn, is due to the fact that dirosine present in the skin is oxidized to melanin by the action of tyrosinase, and this melanin is produced in excess. has been done.
従来より、この色素沈着の予防或いは治療を目的として
、アスコルビン酸が使用されている。Conventionally, ascorbic acid has been used for the purpose of preventing or treating pigmentation.
しかし、アスコルビン酸は、熱や光に対して極めて不安
定で、酸化され昌<、特に水系の化粧料中においては、
分解して変臭1着色を招く原因となる。However, ascorbic acid is extremely unstable to heat and light, and is susceptible to oxidation, especially in water-based cosmetics.
It decomposes and causes odor and discoloration.
これらの問題点を解決する為、アスコルビン酸高級脂肪
酸エステル、アスコルビン酸硫酸エステル、L−アスコ
ルビン酸りん酸マグふシウム1 トコフェロール−L−
アスコルビン酸−2−りん酸エステル、トコフェロール
−し−アスコルビン酸6−ジカルボン酸ジエステル等の
各種のアスコルビン酸誘導体が使用されている。In order to solve these problems, we developed ascorbic acid higher fatty acid ester, ascorbic acid sulfate ester, L-ascorbic acid phosphate magfusium 1, tocopherol-L-
Various ascorbic acid derivatives such as ascorbic acid 2-phosphate and tocopherol-disascorbic acid 6-dicarboxylic acid diester are used.
しかし、アスコルビン酸高級脂肪酸エステルは、安定性
は改善されているものの、美白効果が弱い。However, although ascorbic acid higher fatty acid ester has improved stability, it has a weak whitening effect.
アスコルビン酸硫酸エステルは、水溶性である為、油系
の化粧料に配合しづらく、美白効果も弱い
り、−アスコルビン酸りん酸マグネシウムは、美白効果
には優れているが、皮膚透過性が不十分であるため、美
白効果を得る為には、配合料を多くしなければならない
。Ascorbic acid sulfate is water-soluble, so it is difficult to incorporate into oil-based cosmetics and has a weak whitening effect. Magnesium ascorbic acid phosphate has an excellent whitening effect, but has poor skin permeability. Therefore, in order to obtain a whitening effect, the amount of compounding ingredients must be increased.
トコフェロール−I、−アスコルビン酸−2−リん酸エ
ステルの塩は、塩の種類によっては水に不溶のものがあ
る為、処方を組みにくい。Tocopherol-I, -ascorbic acid-2-phosphate salts are difficult to formulate because some salts are insoluble in water, depending on the type of salt.
F記の欠点を克服するものとして、トコフェロール−し
−アスコルビン酸−6−ジカルボン酸ジエステルが提案
されている(特開昭62187470)。しかしこの化
合物はビタミンCの油溶性が高められており、高い美白
効果を有しているものの、保存によって分解し易く、活
性の低下が著しいという問題点がある。Tocopherol-shi-ascorbic acid-6-dicarboxylic acid diester has been proposed to overcome the drawbacks of item F (Japanese Patent Application Laid-Open No. 62187470). However, although this compound has increased oil solubility of vitamin C and has a high whitening effect, it has the problem that it is easily decomposed during storage and its activity is significantly reduced.
[発明が解決しようとする課題〕
従って本発明の目的は、美白効果に優れ、ビタミンCの
溶解性が改善されており、しかもビタミンCの保存安定
性に優れた、美白化粧料を提供することにある。[Problems to be Solved by the Invention] Therefore, an object of the present invention is to provide a whitening cosmetic that has excellent whitening effects, improved solubility of vitamin C, and excellent storage stability of vitamin C. It is in.
本発明は、
(1) 下記一般式(1)又は(II)で表されるア
スコルビン酸誘導体を含有することを特徴とする美白化
粧料。The present invention provides: (1) A whitening cosmetic comprising an ascorbic acid derivative represented by the following general formula (1) or (II).
OH ○1 (弐 (II)中R は、 を表し、R,、R,は、H又はCHsを表す。OH ○1 (Two (II) Medium R teeth, , R,, R, represents H or CHs.
R6は、炭素数1〜20の直鎖又は分岐鎖の、飽和又は
不飽和の炭化水素基、或いは、−R,−A−R,−基を
表し、R,、R,は、炭素数1〜12の直鎖又は分岐鎖
の、飽和又は不飽和の炭化水素基、Aは、−〇−7−C
o−、−0CO−−CH(CH)
CH(NRs Rq ) −1NR1゜−NR,、−C
O−のいずれかを表す。R6 represents a linear or branched, saturated or unsaturated hydrocarbon group having 1 to 20 carbon atoms, or a -R, -A-R, - group; ~12 linear or branched, saturated or unsaturated hydrocarbon groups, A is -〇-7-C
o-, -0CO--CH(CH) CH(NRs Rq) -1NR1゜-NR,, -C
Represents either O-.
又、Re−R++は、H1低級アルキル基脂肪族低級ア
ンル基、芳香族アシル基のいずれかを表す。)
(2) 下記一般式(III)又は(TV)で表され
るアスコルビン酸誘導体を含有することを特徴と(但し
、R,、R,は、(r)、(II)の場合と同じである
。)
である。Moreover, Re-R++ represents either H1 lower alkyl group, aliphatic lower anru group, or aromatic acyl group. ) (2) Characterized by containing an ascorbic acid derivative represented by the following general formula (III) or (TV) (provided that R, , R, are the same as in (r) and (II)) ).
本発明に用いられる一般式(1)〜(IV)で表される
アスコルビン酸m 8体は、例えば次のようにして製造
することができる。Ascorbic acid m8 bodies represented by general formulas (1) to (IV) used in the present invention can be produced, for example, as follows.
ハロカルボン酸の酸ハロゲン化物トトコフエロールを、
ピリジン等の塩基の存在下、エーテル等の非反応性溶媒
中で反応させる。Acid halide totocopherol of halocarboxylic acid,
The reaction is carried out in the presence of a base such as pyridine in a non-reactive solvent such as ether.
次に、L〜アスコルビン酸をアセトン溶媒中でアセチル
クロライドと反応させ、室温下で懸濁した後、冷却する
。得られた結晶を、冷やしたアセトンで洗浄し、乾燥す
ることによって、5.60−イソプロピリデン−L−ア
スコルビン酸を調製する。Next, L~ascorbic acid is reacted with acetyl chloride in an acetone solvent, suspended at room temperature, and then cooled. 5.60-isopropylidene-L-ascorbic acid is prepared by washing the obtained crystals with chilled acetone and drying.
得られた5、6−0−イソプロピリデン−しA、THF
等の溶媒中、炭酸カリウム、炭酸ナトJウム、水酸化ナ
トリウム1水酸化カリウム等の塩基の存在下で反応させ
、エーテル合成を行うことによって、−C式(III)
又は(IV)で表される化合物を製造することができる
。The obtained 5,6-0-isopropylidene-A, THF
By reacting in the presence of a base such as potassium carbonate, sodium carbonate, sodium hydroxide monopotassium hydroxide, etc. to synthesize an ether, -C formula (III)
Alternatively, a compound represented by (IV) can be produced.
一般式(1)又は(Il)で表される化合物は、化合物
(I[I)又は(TV)をTHF等の溶媒に熔かし、I
N塩酸等の酸を加えて撹拌し、アスコルビン酸の5,6
位の保護基をはずすことによって得ることができる。The compound represented by the general formula (1) or (Il) can be obtained by dissolving the compound (I[I) or (TV) in a solvent such as THF,
Add an acid such as N-hydrochloric acid and stir.
It can be obtained by removing the protecting group at position.
一般式(1)〜(八7)で表される化合物を製造する為
に用いられるハロカルボン酸の酸ハロゲン化物としては
、例えば以下のようなものが挙げらX (CH2
)3
−Y
(CH2)2
X
CH。Examples of acid halides of halocarboxylic acids used to produce compounds represented by formulas (1) to (87) include the following:
)3-Y(CH2)2XCH.
)、CH CH。), CH CH.
)。).
(CHf)、−C (CH。(CHf), -C (CH.
(cH。(cH.
)h H2 (CH2 )。)h H2 (CH2 ).
II −Y CH。II -Y CH.
(CH2 (CH2)2C CH。(CH2 (CH2)2C CH.
(C1(2)SC
(CH2)3
II II
−Y、 X−(C)I、>80−CCCH2’)、、
−C−Y。(C1(2)SC (CH2)3 II II -Y, X-(C)I, >80-CCCH2'),,
-C-Y.
○ H0 (I X−(CH2)2CHCH,−C−Y。○H0 (I X-(CH2)2CHCH, -C-Y.
OH0
X−(CH2)、C)((CHt ’)t−c −
Y。OH0 X-(CH2), C)((CHt')t-c-
Y.
OHC2N5
X−(CH2)SCH(CH,)、CH(CH,)SN
(CH3)! 0
(CH2)、CH(CH2)、−C
χ −
(CH2)2NH
(CH2)。OHC2N5 X-(CH2)SCH(CH,), CH(CH,)SN
(CH3)! 0 (CH2), CH(CH2), -Cx-(CH2)2NH (CH2).
(C11□ンicl二1=cH (C)(2)SNH (CH,)。(C11□nicl21=cH (C) (2) SNH (CH,).
CI+10
(CH2)3N
(C112)、CH=CH(CH2)6−C−YHNC
OCH30
X−(CH2)、CHCH2−C,−Y0=C−Ph
○
X−(C)(! )3N (CH2)、−C−YC
H3−CO0
X−(CH2)、N−C−(CH,)、−C−Y(但し
、X、Yはハロゲン、Phはフェニル基を表す。)
これらを用いて製造されたアスコルビン酸誘導体の、チ
ロシナーゼ活性阻害率を後述する方法で測定し、結果を
第1表に示した。CI+10 (CH2)3N (C112), CH=CH(CH2)6-C-YHNC
OCH30 X-(CH2), CHCH2-C, -Y0=C-Ph
○ X-(C)(! )3N (CH2), -C-YC
H3-CO0 The inhibition rate of tyrosinase activity was measured by the method described below, and the results are shown in Table 1.
尚、試料中の化合物(])、 (II)の濃度は、2
重量%である。In addition, the concentration of compounds (]) and (II) in the sample is 2
Weight%.
本発明の美白化粧料における、一般式(1)〜(■)で
表されるし一アスコルビン酸誘導体の含を量は、該当化
粧料の総量に対して0.1〜10重量%(以下重量%を
wt%と略記する。)が好ましい。In the whitening cosmetic of the present invention, the content of the monoascorbic acid derivatives represented by general formulas (1) to (■) is 0.1 to 10% by weight (hereinafter referred to as weight) based on the total amount of the cosmetic. % is abbreviated as wt%) is preferred.
0、1 w t%未満だと所望の効果が得にくく、lQ
wt%を越えても効果の大きな増加は望めない。If it is less than 0.1 wt%, it is difficult to obtain the desired effect, and lQ
Even if the amount exceeds wt%, no significant increase in effectiveness can be expected.
本発明の美白化粧料の剤型は、特に限定されるものでな
く、クリーム状、乳液状、ローション状。The dosage form of the whitening cosmetic of the present invention is not particularly limited, and may be cream, emulsion, or lotion.
パウダー状等々の通常の化粧料の剤型を適用することが
出来る。Usual cosmetic formulations such as powder can be used.
又、他の成分として、香料、防腐剤2着色料皮膚栄養剤
などを、本発明の目的を達成する範囲内で適宜配合し得
る。Further, as other ingredients, fragrances, preservatives, colorants, skin nutrients, etc. may be appropriately incorporated within the scope of achieving the object of the present invention.
以下、実施例にて本発明を説明する。 The present invention will be explained below with reference to Examples.
実施例に記載の■保存安定性試験(チロシナーゼ活性阻
害率の安定性)■メラニン形成抑制試験■皮膚色明度回
復試験、■美白実用試験は、下記の通りに実施した。■ Storage stability test (stability of tyrosinase activity inhibition rate) ■ Melanin formation inhibition test ■ Skin color brightness recovery test, and ■ Whitening practical test described in Examples were conducted as follows.
■ 保存安定性試験
下記の方法にて、本発明の美白化粧料の、調製直後、2
0°C3ケ月保存後、45℃3ケ月保存後のチロシナー
ゼ活性阻害率を測定し、保存安定性を評価した。■ Storage stability test Immediately after preparation of the whitening cosmetic of the present invention, 2
After 3 months of storage at 0°C and 3 months of storage at 45°C, the inhibition rate of tyrosinase activity was measured to evaluate storage stability.
ハーディングーバッセイ(Harding−Passa
y )マウスメラノーマから抽出した酵素チロシナーゼ
を使用し、その酵素活性をドーパ−クロームの475n
mの吸光度を測定するフォトメトリー法によってしらべ
た。Harding-Passa
y) Using the enzyme tyrosinase extracted from mouse melanoma, its enzyme activity was determined by 475n of dopachrome.
This was investigated by photometry, which measures the absorbance of m.
本発明の美白化粧料(以下試料と称す、) 0.9m、
lを採取し、L−チロシン溶液(0,3m g /m
l)を1mlとマツクルペイン氏の緩衝液(p H6,
8)を1ml加え、37℃の恒温水槽中で10分間イン
キュベートした後、これにチロシナーゼ溶液(1m g
/ m l )を0.1 m jl!加えてよく撹拌
し、37°Cに保って10分後、475nmで吸光度(
D +)を測定する。加熱失活させたチロシナーゼを用
いて同様に反応させた吸光度(D2)および、試料の代
わりに水のみを用いた対照試験品の吸光度(D、)を測
定し、次式からチロシナーゼ活性阻害率を算出する。Whitening cosmetics of the present invention (hereinafter referred to as samples) 0.9m,
L-tyrosine solution (0.3 mg/m
1 ml) and Matsukurupain's buffer (pH 6,
After adding 1 ml of 8) and incubating for 10 minutes in a constant temperature water bath at 37°C, tyrosinase solution (1 mg
/ m l ) to 0.1 m jl! Add it, stir well, keep it at 37°C for 10 minutes, and then measure the absorbance at 475 nm (
D+). The absorbance (D2) of a similar reaction using heat-inactivated tyrosinase and the absorbance (D,) of a control test product using only water instead of the sample were measured, and the tyrosinase activity inhibition rate was calculated from the following formula. calculate.
チロシナーゼ活性阻害率(%)
D−Dz
■ メラニン形成抑制試験
F】系黒色モルモット(雄、約8闇令、平均体重350
g)の背部皮膚を刈上後、脱毛クリームにより完全除毛
し、翌日より各試料を除毛部皮膚に毎日−回、4cm”
当り0.2 g ”塗布し、閉塞貼布した。尚1試料
に対して動物は一群10匹使用した。Tyrosinase activity inhibition rate (%) D-Dz ■ Melanin formation inhibition test F] Black guinea pig (male, about 8 years old, average weight 350
g) After cutting the back skin, completely remove the hair with hair removal cream, and from the next day, apply each sample to the skin of the hair-removed area once a day in a 4 cm area.
Each sample was applied in an amount of 0.2 g, and an occluded patch was applied. A group of 10 animals was used for each sample.
メラニン形成抑制効果の評価は、試験開始後1ケ月後に
実施し、高速分光色彩計を用いて塗布部の明度(Y、)
と非塗布部の明度(Yo)との比の値■ 皮膚色明度回
復試験
被試験者20名の背部皮膚に試料塗布部位と非塗布部位
とを設定し、両部位にU V −B 9M域の紫外線を
最小紅斑量の2倍量照射し、1週間の後、各々の皮膚の
基準明度(VO値、■。′値)を測定した。引続いて塗
布部位には試料を1日1回ずつ3ケ月間連続塗布し、3
,7.13週間後の塗布部位及び非塗布部位の皮膚の回
復明度(v、・・・値。The melanin formation inhibitory effect was evaluated one month after the start of the test, and the brightness (Y,) of the applied area was evaluated using a high-speed spectrocolorimeter.
and the brightness (Yo) of the non-applied area■ Skin color brightness recovery test A sample application area and a non-application area were set on the back skin of 20 test subjects, and both areas were exposed to UV-B 9M range. UV rays were irradiated in an amount twice the minimum amount of erythema, and after one week, the standard brightness (VO value, ■.' value) of each skin was measured. Subsequently, the sample was continuously applied to the application site once a day for 3 months.
, 7. Recovery brightness (v, ... value of the skin of the application site and non-application site after 13 weeks).
■ア”・・・値)を測定して、第2表の判定基準により
、皮膚色の回復評価を実施した。(a) value) was measured, and skin color recovery evaluation was performed according to the criteria shown in Table 2.
尚、皮膚の明度(V値)は高速分光色彩計で測定して得
られたマンセル値よす算出した。The brightness (V value) of the skin was calculated using the Munsell value obtained by measuring with a high-speed spectrocolorimeter.
被試験者20名の評価点の平均(lI資求め、皮膚第
表
■ 美白実用試験
シミ、ソバカス、日焼は等を訴える被試験者各20名の
傾面に試料を朝夕1回ずつ3ケ月間連続塗布した後の改
善効果を調査した。評価はシミソバカス、日焼けが各々
改善されたと回答した被試験者の数で示した。The average of the evaluation scores of 20 test subjects (lI calculation, skin table ■ Whitening practical test Samples were applied to the slope of each of 20 test subjects who complained of age spots, freckles, sunburn, etc., once in the morning and once in the evening for 3 months. The improvement effect after continuous application was investigated.Evaluation was expressed by the number of test subjects who answered that their skin freckles and sunburn were improved.
実施例1〜8.比較例1〜4
(二層型ローション)
下記の組成に於いて第3表に示す通りにL−アスコルビ
ン酸誘導体の種類及び含有量を変えて、実施例、比較例
である二層型ローションを調製して詩誌験を実施した。Examples 1-8. Comparative Examples 1 to 4 (Two-layer lotion) Two-layer lotions as Examples and Comparative Examples were prepared by changing the type and content of the L-ascorbic acid derivative as shown in Table 3 in the composition below. I prepared it and conducted a poetry review.
その結果を第3表に示した。The results are shown in Table 3.
(1) &Il成
(2) iI製方法
(A)成分の内、油溶性のものは(B)成分(油相)中
に、また水溶性のものは(C)成分(水相)中に、必要
に応して加熱して均一に溶解する。(1) &Il formation (2) iI production method Among the components (A), oil-soluble ones are added to the (B) ingredient (oil phase), and water-soluble ones are added to the (C) ingredient (aqueous phase). , if necessary, heat to dissolve uniformly.
次いで、(B)成分溶液、(C)成分溶液を均一に混合
攪拌分散した後、容器に充填する。Next, the component solution (B) and the component solution (C) are uniformly mixed, stirred and dispersed, and then filled into a container.
使用時には内容物を均一に振盪分散して使用す(3)
特性
第3表に示す如く、アスコルビン酸誘導体を含有しない
比較例1は、チロシナーゼの活性を阻害しない為、メラ
ニン形成を抑制せず(YT/YO<1)皮膚色の明度回
復効果もほとんどなく、実用試験の結果も悪かった。
アスコルビン酸誘導体として、L−アスコルビン酸リン
酸マグネシウムを含有する比較例2は、保存安定性は良
好であるが、メラニン形成抑制効果、皮膚色明度回復効
果に乏しく、実用試験の結果も良くなかった。When using, shake and disperse the contents evenly (3)
As shown in Table 3, Comparative Example 1, which does not contain ascorbic acid derivatives, does not inhibit tyrosinase activity, does not inhibit melanin formation (YT/YO<1), and has almost no effect on restoring skin color brightness. The results of the practical test were also poor.
Comparative Example 2 containing L-ascorbic acid magnesium phosphate as an ascorbic acid derivative had good storage stability, but had poor melanin formation inhibiting effect and skin color brightness recovery effect, and the results of practical tests were also poor. .
アスコルビン酸誘導体として、α−トコフェロール−し
−アスコルビン酸−6−コハク酸ジエステルを含有する
比較例3は、比較例1.2に比べてメラニン形成抑制効
果、皮膚色明度回復効果は多少アップしているものの、
保存安定性が悪く、実用試験の結果も良くなかった。Comparative Example 3, which contains α-tocopherol-shi-ascorbic acid-6-succinic acid diester as an ascorbic acid derivative, has a somewhat higher melanin formation inhibiting effect and skin color brightness recovery effect than Comparative Example 1.2. Although there are
The storage stability was poor, and the results of practical tests were also poor.
アスコルビン酸誘導体としてα−トコフェロール−し−
アスコルビン酸−2−リン酸エステルを含有する比較例
4も、メラニン形成抑制効果1皮膚色明度回復効果は不
十分であり、実用試験の結果も良くなかった。α-tocopherol as an ascorbic acid derivative
In Comparative Example 4 containing ascorbic acid-2-phosphate ester, the melanin formation inhibiting effect 1 skin color brightness recovery effect was also insufficient, and the results of the practical test were also poor.
それに比べてアスコルビン酸誘導体として、−般式(1
)〜(IV)で表される化合物を含有する実施例1〜8
は、高いチロシナーゼ活性阻害率を存し、しかも保存安
定性が良好で、メラニン形成抑制効果及び皮膚色明度回
復効果に優れており、しかも実用試験の結果も良がった
。In comparison, ascorbic acid derivatives have the general formula (1
Examples 1 to 8 containing compounds represented by ) to (IV)
has a high tyrosinase activity inhibition rate, good storage stability, excellent melanin formation inhibiting effect and skin color brightness recovery effect, and also showed good results in practical tests.
実施例9〜16.比較例5〜8
(スキンクリーム)
実施例1と同様に、下記の組成に於いて種々の実施例、
比較例のスキンクリームを調製して諸試組成
(2) tA製製法
法^)成分の内、油溶性のものは(B)成分中に、また
水溶性のものは(C)成分中に混合し、(B)成分と(
C)成分を各々均一に加熱溶解して温度を80°Cにす
る0次いで、(B)成分中に(C)成分を注入攪拌混合
した後、
撹拌しながら温度を3
°C
(3) 特性
第4表に示す如く、比較例5〜8に対して本発明の美白
化粧料である実施例9〜16は諸試験に於いて全て良好
な結果を示し、美白効果も優れている。Examples 9-16. Comparative Examples 5 to 8 (Skin Cream) Similar to Example 1, various Examples with the following composition,
Comparative skin cream was prepared and various test compositions (2) tA manufacturing method ^) Among the ingredients, oil-soluble ones were mixed into the (B) component, and water-soluble ones were mixed into the (C) component. and (B) component and (
C) Dissolve each component uniformly by heating to bring the temperature to 80°C.Next, pour component (C) into component (B) and mix with stirring, then lower the temperature to 3°C while stirring. (3) Characteristics As shown in Table 4, in contrast to Comparative Examples 5 to 8, Examples 9 to 16, which are whitening cosmetics of the present invention, all showed good results in various tests and had excellent whitening effects.
実施例17〜24.比較例9〜12
(乳液)
下記の組成に於いて種々の実施例、比較例の乳液を調製
して諸試験を実施した。その結果を第5鮒成
(2) 調製方法
(A)成分の内、油溶性のものは(B)成分中に、また
水溶性のものは(C)成分中に混合し、(B)成分と(
C)成分を各々均一に加熱溶解して温度を80°Cにす
る。次いで、(B)成分中に(C)成分を注入攪拌混合
した後、
攪拌しながら温度を3
°C
(3) 特性
第5表に示す如く、比較例9〜12に対して本発明の美
白化粧料である実施例17〜24は、詩誌験に於いて全
て良好な結果を示し、美白効果も優れている。Examples 17-24. Comparative Examples 9 to 12 (Emulsions) Emulsions of various Examples and Comparative Examples having the following compositions were prepared and various tests were conducted. The results are summarized in Step 5 (2) Preparation Method Among the ingredients in (A), oil-soluble ones are mixed in the (B) ingredient, water-soluble ones are mixed in the (C) ingredient, and the (B) ingredient is mixed in the (C) ingredient. and(
C) Uniformly heat and melt each component to bring the temperature to 80°C. Next, the component (C) was injected into the component (B) and mixed with stirring, and then the temperature was raised to 3 °C while stirring. Examples 17 to 24, which are cosmetics, all showed good results in the poetry test and had excellent whitening effects.
(発明の効果]
以上記載の如く、本発明の美白化粧料は、従来のし一ア
スコルビン酸誘導体を含有する美白化粧料と比較して、
美白効果および保存安定性において顕著に優れているこ
とは明らかである。(Effects of the Invention) As described above, the whitening cosmetic of the present invention has the following effects compared to the conventional whitening cosmetic containing an ascorbic acid derivative:
It is clear that it is significantly superior in whitening effect and storage stability.
Claims (2)
ルビン酸誘導体を含有することを特徴とする美白化粧料
。 ▲数式、化学式、表等があります▼・・・( I ) ▲数式、化学式、表等があります▼・・・(II) (式( I )、(II)中R_1、R_2は、 ▲数式、化学式、表等があります▼ を表し、R_3、R_4は、H又はCH_3を表す。 R_5は、炭素数1〜20の直鎖又は分岐鎖の、飽和又
は不飽和の炭化水素基、或いは、−R_6−A−R_7
−基を表し、R_6、R_7は、炭素数1〜12の直鎖
又は分岐鎖の、飽和又は不飽和の炭化水素基、Aは、−
O−、 −CO−、−OCO−、−CH(OH)−、−CH(N
R_8R_9)−、−NR_1_0−、−NR_1_1
−CO−のいずれかを表す。 又、R_8〜R_1_1は、H、低級アルキル基、脂肪
族低級アシル基、芳香族アシル基のいずれかを表す。)(1) A whitening cosmetic characterized by containing an ascorbic acid derivative represented by the following general formula (I) or (II). ▲There are mathematical formulas, chemical formulas, tables, etc.▼...(I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼...(II) (R_1 and R_2 in formulas (I) and (II) are ▲Mathematical formulas, There are chemical formulas, tables, etc. -A-R_7
- group, R_6 and R_7 are linear or branched, saturated or unsaturated hydrocarbon groups having 1 to 12 carbon atoms, A is -
O-, -CO-, -OCO-, -CH(OH)-, -CH(N
R_8R_9)-, -NR_1_0-, -NR_1_1
-CO- represents either. Moreover, R_8 to R_1_1 represent any one of H, a lower alkyl group, an aliphatic lower acyl group, and an aromatic acyl group. )
ルビン酸誘導体を含有することを特徴とする美白化粧料
。 ▲数式、化学式、表等があります▼・・・(III) ▲数式、化学式、表等があります▼・・・(IV) (但し、R_1、R_2は、( I )、(II)の場合と
同じである。(2) A whitening cosmetic containing an ascorbic acid derivative represented by the following general formula (III) or (IV). ▲There are mathematical formulas, chemical formulas, tables, etc.▼...(III) ▲There are mathematical formulas, chemical formulas, tables, etc.▼...(IV) (However, R_1 and R_2 are the same as in the case of (I) and (II). It's the same.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27193890A JPH04149114A (en) | 1990-10-09 | 1990-10-09 | Whitening cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27193890A JPH04149114A (en) | 1990-10-09 | 1990-10-09 | Whitening cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04149114A true JPH04149114A (en) | 1992-05-22 |
Family
ID=17506931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP27193890A Pending JPH04149114A (en) | 1990-10-09 | 1990-10-09 | Whitening cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04149114A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2727412A1 (en) * | 1994-11-28 | 1996-05-31 | Rocher Yves Biolog Vegetale | New oxidn.-resistant opt. O-esterified hydroxy:ester cpds. |
-
1990
- 1990-10-09 JP JP27193890A patent/JPH04149114A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2727412A1 (en) * | 1994-11-28 | 1996-05-31 | Rocher Yves Biolog Vegetale | New oxidn.-resistant opt. O-esterified hydroxy:ester cpds. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003095915A (en) | Skin care composition | |
| JPH11199426A (en) | Cosmetic | |
| JP2684615B2 (en) | Skin cosmetics | |
| KR100297347B1 (en) | A W/O type emulsion cosmetic composition containing the stabilized L-ascorbic acid and a method for preparing the same | |
| JP2578394B2 (en) | Whitening agent | |
| JP2663136B2 (en) | Whitening cosmetics | |
| JPH04149115A (en) | Whitening cosmetic | |
| JPS61207312A (en) | Skin-beautifying cosmetic | |
| JPH04149117A (en) | Skin-beautifying cosmetic | |
| JPH04149113A (en) | Whitening cosmetic | |
| JPS62129212A (en) | Cosmetic | |
| JP3517068B2 (en) | Skin cosmetics | |
| JP3354768B2 (en) | Skin cosmetics | |
| JP4137016B2 (en) | Emulsified external skin preparation | |
| JP2906269B2 (en) | External preparation for skin | |
| JPH0425249B2 (en) | ||
| JP3686772B2 (en) | Topical skin preparation | |
| JP2003206279A (en) | Pyridoxine derivative and skin care preparation and hair cosmetic containing the same pyridoxine derivative | |
| JPH08337516A (en) | One-part hair dye composition | |
| JPH0782127A (en) | Cosmetic | |
| JP4140024B2 (en) | Melanin production inhibitor | |
| JP2744485B2 (en) | Whitening cosmetics | |
| JP3045604B2 (en) | Whitening cosmetics | |
| JP4336271B2 (en) | Emulsified external skin preparation with yogurt-like appearance | |
| JPH0363207A (en) | Skin cosmetic |